Literature DB >> 9014776

Oxytocin increases thresholds of colonic visceral perception in patients with irritable bowel syndrome.

D Louvel1, M Delvaux, A Felez, J Fioramonti, L Bueno, Y Lazorthes, J Frexinos.   

Abstract

AIM: The effects of oxytocin on colonic perception of intraluminal distension were evaluated in 26 patients with irritable bowel syndrome (IBS), using a flaccid bag placed in the descending colon and connected to a computerised barostat.
METHOD: Symptomatic responses (first sensation and pain) were evaluated during isobaric distensions (4 mm Hg increments, five minute duration, five minute interval with return to zero pressure between each step), performed automatically by the barostat, during a continuous infusion of placebo or various doses of oxytocin (10, 20, 30, and 50 mU/min).
RESULTS: The distension pressure (mean (SD)) required to induce a first abdominal sensation was 17.3 (5.5) mm Hg on placebo, 19.9 (5.8) on oxytocin 10 mU/min (NS), 22.3 (6.0) mm Hg on oxytocin 20 mU/min (p < 0.01), 23.1 (6.6) mm Hg on oxytocin 30 mU/min (p < 0.01), and 24.0 (7.1) mm Hg on oxytocin 50 mU/min (p < 0.01). The distension pressure required to induce pain was 24.8 (6.3) mm Hg on placebo, 26.0 (5.8) on oxytocin 10 mU/min (NS), 33.3 (7.8) mm Hg on oxytocin 20 mU/min (p < 0.01), 34.2 (7.6) mm Hg on oxytocin 30 mU/min (p < 0.01), and 34.3 (7.9) mm Hg on oxytocin 50 mU/ min (p < 0.01). Compliance curves were not different after placebo and oxytocin injection at the different doses. Naloxone did not inhibit the effect of oxytocin. Oxytocin also did not alter somatic perception, characterised by the RIII reflex at the level of the biceps femori.
CONCLUSIONS: Oxytocin significantly increases thresholds for visceral perception in IBS patients at doses equal or to greater than 20 mU/min, possibly by acting at the level of visceral afferents.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9014776      PMCID: PMC1383401          DOI: 10.1136/gut.39.5.741

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  36 in total

1.  Comparative study of perceived pain and nociceptive flexion reflex in man.

Authors:  Jean Clau de Willer
Journal:  Pain       Date:  1977-02       Impact factor: 6.961

2.  Antinociceptive effects of intraventricular or systemic administration of vasopressin in the rat.

Authors:  G G Berntson; B S Berson
Journal:  Life Sci       Date:  1980-02-11       Impact factor: 5.037

3.  Evaluation of colonic myoelectrical activity in health and functional disorders.

Authors:  L Bueno; J Fioramonti; Y Ruckebusch; J Frexinos; P Coulom
Journal:  Gut       Date:  1980-06       Impact factor: 23.059

4.  Colonic myoelectrical activity in irritable-bowel syndrome. Effect of eating and anticholinergics.

Authors:  M A Sullivan; S Cohen; W J Snape
Journal:  N Engl J Med       Date:  1978-04-20       Impact factor: 91.245

5.  Irritable bowel syndrome: physiological and psychological differences between diarrhea-predominant and constipation-predominant patients.

Authors:  W E Whitehead; B T Engel; M M Schuster
Journal:  Dig Dis Sci       Date:  1980-06       Impact factor: 3.199

6.  Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome.

Authors:  J Ritchie
Journal:  Gut       Date:  1973-02       Impact factor: 23.059

7.  Vasopressin and oxytocin in the rat spinal cord: analysis of their role in the control of nociception.

Authors:  M J Millan; C Schmauss; M H Millan; A Herz
Journal:  Brain Res       Date:  1984-09-10       Impact factor: 3.252

8.  Site of pain from the irritable bowel.

Authors:  E T Swarbrick; J E Hegarty; L Bat; C B Williams; A M Dawson
Journal:  Lancet       Date:  1980-08-30       Impact factor: 79.321

9.  Supraspinal influences on nociceptive flexion reflex and pain sensation in man.

Authors:  J C Willer; F Boureau; D Albe-Fessard
Journal:  Brain Res       Date:  1979-12-21       Impact factor: 3.252

10.  Vasopressin analgesia: specificity of action and non-opioid effects.

Authors:  J H Kordower; R J Bodnar
Journal:  Peptides       Date:  1984 Jul-Aug       Impact factor: 3.750

View more
  27 in total

1.  Specific and cross over effects of massage for muscle soreness: randomized controlled trial.

Authors:  Kenneth Jay; Emil Sundstrup; Stine D Søndergaard; David Behm; Mikkel Brandt; Charlotte A Særvoll; Markus D Jakobsen; Lars L Andersen
Journal:  Int J Sports Phys Ther       Date:  2014-02

2.  Oxytocin nasal spray in fibromyalgic patients: additional information : reply to the comment to the editor entitled "future directions for the investigation of intranasal oxytocin and pain".

Authors:  Roberta Agabio; Sergio Mameli; Salvatore Sardo; Luigi Minerba; Maria Rosaria Melis
Journal:  Rheumatol Int       Date:  2014-07-29       Impact factor: 2.631

3.  Oxytocin regulates gastrointestinal motility, inflammation, macromolecular permeability, and mucosal maintenance in mice.

Authors:  Martha G Welch; Kara G Margolis; Zhishan Li; Michael D Gershon
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-08-21       Impact factor: 4.052

Review 4.  Oxytocin - a multifunctional analgesic for chronic deep tissue pain.

Authors:  Burel R Goodin; Timothy J Ness; Meredith T Robbins
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

5.  Augmented Visceral Perception.

Authors:  William L. Hasler
Journal:  Curr Treat Options Gastroenterol       Date:  2001-08

6.  Intrathecal oxytocin inhibits visceromotor reflex and spinal neuronal responses to noxious distention of the rat urinary bladder.

Authors:  Mitchell P Engle; Timothy J Ness; Meredith T Robbins
Journal:  Reg Anesth Pain Med       Date:  2012 Sep-Oct       Impact factor: 6.288

7.  Proximal colon distension induces Fos expression in oxytocin-, vasopressin-, CRF- and catecholamines-containing neurons in rat brain.

Authors:  Lixin Wang; Vicente Martínez; Muriel Larauche; Yvette Taché
Journal:  Brain Res       Date:  2008-10-15       Impact factor: 3.252

8.  Prognosis of constipation: clinical factors and colonic transit time.

Authors:  F de Lorijn; M P van Wijk; J B Reitsma; R van Ginkel; J A J M Taminiau; M A Benninga
Journal:  Arch Dis Child       Date:  2004-08       Impact factor: 3.791

Review 9.  Pharmacotherapy: non-serotonergic mechanisms.

Authors:  R Spiller
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

10.  Polymorphism in the oxytocin promoter region in patients with lactase non-persistence is not related to symptoms.

Authors:  Mikael Truedsson; Joyce Carlson; Magnus Simrén; Bodil Ohlsson
Journal:  BMC Gastroenterol       Date:  2009-11-30       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.